237 related articles for article (PubMed ID: 31355685)
1. Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years.
Rose F; Bloom S; Tan T
Expert Opin Drug Discov; 2019 Nov; 14(11):1151-1159. PubMed ID: 31355685
[No Abstract] [Full Text] [Related]
2. Cracking the combination: Gut hormones for the treatment of obesity and diabetes.
Alexiadou K; Anyiam O; Tan T
J Neuroendocrinol; 2019 May; 31(5):e12664. PubMed ID: 30466162
[TBL] [Abstract][Full Text] [Related]
3. Future therapies for obesity.
Melson E; Miras AD; Papamargaritis D
Clin Med (Lond); 2023 Jul; 23(4):337-346. PubMed ID: 37524416
[TBL] [Abstract][Full Text] [Related]
4. Gut hormones as therapeutic agents in treatment of diabetes and obesity.
Tan T; Bloom S
Curr Opin Pharmacol; 2013 Dec; 13(6):996-1001. PubMed ID: 24060699
[TBL] [Abstract][Full Text] [Related]
5. Gut hormone co-agonists for the treatment of obesity: from bench to bedside.
Nogueiras R; Nauck MA; Tschöp MH
Nat Metab; 2023 Jun; 5(6):933-944. PubMed ID: 37308724
[TBL] [Abstract][Full Text] [Related]
6. Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?
Kokkinos A; Tsilingiris D; le Roux CW; Rubino F; Mantzoros CS
Metabolism; 2019 Nov; 100():153960. PubMed ID: 31412266
[TBL] [Abstract][Full Text] [Related]
7. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
8. New Targets for Drug Treatment of Obesity.
Valsamakis G; Konstantakou P; Mastorakos G
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():585-605. PubMed ID: 28061687
[TBL] [Abstract][Full Text] [Related]
9. Gut hormone polyagonists for the treatment of type 2 diabetes.
Brandt SJ; Götz A; Tschöp MH; Müller TD
Peptides; 2018 Feb; 100():190-201. PubMed ID: 29412819
[TBL] [Abstract][Full Text] [Related]
10. Peptide-based multi-agonists: a new paradigm in metabolic pharmacology.
Brandt SJ; Müller TD; DiMarchi RD; Tschöp MH; Stemmer K
J Intern Med; 2018 Dec; 284(6):581-602. PubMed ID: 30230640
[TBL] [Abstract][Full Text] [Related]
11. Latest approaches for the treatment of obesity.
Jackson VM; Breen DM; Fortin JP; Liou A; Kuzmiski JB; Loomis AK; Rives ML; Shah B; Carpino PA
Expert Opin Drug Discov; 2015; 10(8):825-39. PubMed ID: 25967138
[TBL] [Abstract][Full Text] [Related]
12. Gut Peptide Agonism in the Treatment of Obesity and Diabetes.
Grandl G; Novikoff A; DiMarchi R; Tschöp MH; Müller TD
Compr Physiol; 2019 Dec; 10(1):99-124. PubMed ID: 31853954
[TBL] [Abstract][Full Text] [Related]
13. Treating obesity: is it all in the gut?
Davenport RJ; Wright S
Drug Discov Today; 2014 Jul; 19(7):845-58. PubMed ID: 24291217
[TBL] [Abstract][Full Text] [Related]
14. Gut hormones as peripheral anti obesity targets.
Small CJ; Bloom SR
Curr Drug Targets CNS Neurol Disord; 2004 Oct; 3(5):379-88. PubMed ID: 15544446
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome.
Alexiadou K; Tan TM
Curr Diab Rep; 2020 May; 20(7):26. PubMed ID: 32436022
[TBL] [Abstract][Full Text] [Related]
17. Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives.
Quiñones M; Fernø J; Diéguez C; Nogueiras R; Al-Massadi O
Expert Opin Drug Discov; 2019 May; 14(5):421-431. PubMed ID: 30821530
[TBL] [Abstract][Full Text] [Related]
18. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
19. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
20. The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity.
Koliaki C; Liatis S; Dalamaga M; Kokkinos A
Curr Obes Rep; 2020 Sep; 9(3):255-271. PubMed ID: 32647952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
